Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the publication of a peer-reviewed article in the European Journal of Pain on the potential of FABP5 as a therapeutic target for pain management, and these results encourage advancement of ART26.12, a developing analgesic.
Preclinical evidence suggests that inhibition of fatty-acid binding protein 5 (FABP5), as a novel lipid-signalling target, has an analgesic effect on visceral, inflammatory, neuropathic, and joint pain.
Artelo has evaluated ART26.12, a FABP5 inhibitor as a novel, non-opioid pain treatment for diabetic neuropathy, osteoarthritis, cancer bone pain, and peripheral neuropathy caused by chemotherapy across 7 preclinical studies.
The drug has completed a Phase 1 single ascending dose study, and the company expects to initiate a multiple ascending dose study later this year.
ARTL is currently trading at $5.16, up 16.22%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.